Close this search box.

STADA Arzneimittel AG: Legacy of Care with High-quality Pharmaceuticals

TADA Arzneimittel AG | Peter Goldschmidt | CEO
Stada Arzneimittel | Peter Goldschmidt | CEO

Pharmaceutical companies the world over patent the drugs that are derived from their own research. This allows them to have a monopoly in the sales of a product for many years and these companies do not have to worry about competitors when setting prices. Hence, they can charge as high a price for products as they want.

But once an initial supplier’s patent, which generally lasts up to 25 years, expires, other manufacturers of medicines can also produce these long-standing pharmaceutical products and sell them at significantly lower prices. These medicines are called ‘Generics’.

Generics are pharmaceutical drugs that contain the same active pharmaceutical ingredient as the first supplier’s proprietary product. Generics are significantly less expensive, despite their great quality.

A leading manufacturer of high-quality pharmaceuticals, with a long-standing heritage rooted in pharmacies, is the Germany-based company that has carved itself a legacy of care with high-quality pharmaceuticals – STADA Arzneimittel AG.

STADA is highly regarded in the pharmaceutical sector as a reliable and trustworthy partner for over 125 years. With its products, STADA helps protect people and regain a dignified and able life. With its proven Generics, the company ensures that everyday health remains affordable.

And for its employees, STADA facilitates an attractive working environment in which they can develop personally.

STADA focuses on a three-pillar strategy consisting of generics, speciality pharma, and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. Consumer Healthcare brands such as Zoflora®Grippostad®Snup®Aqualor®Vitaprost® and Nizoral® are among the top sellers in their respective product categories. In the financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.

“At STADA, we follow our purpose of ‘Caring for people’s health as a trusted partner’,” remarked the Chairman of the Executive Board and the trailblazing CEO of STADA Group – Peter Goldschmidt. “In pursuit of this purpose, we are committed to further accelerating the successful trajectory of our company,” he added.

Caring for People’s Health

As all success stories do, STADA Arzneimittel’s company history started with a great idea. In 1895, a group of pharmacists had a common objective: The standardized production of medicinal products to ensure an effective and reasonable provision of healthcare for the many. This was the beginning of STADA’s impressive development.

Today, the company is a leading manufacturer of high-quality pharmaceuticals. With a long-standing heritage rooted in pharmacies, the STADA Group is a reliable and trustworthy partner for more than 125 years.

Purpose: Caring for people’s health as a trusted partner

Vision: To be the partner of choice in generics and consumer health, while continuously outgrowing the industry in terms of growth and profitability.

Core Values:

Integrity – “Each and every one of us acts ethically in line with the company’s internal and external standards. Our actions are led by speaking up and respect.”

Entrepreneurship – “Each and every one of us drives new ideas and actions, creating future growth and value.”

Agility – “Each and every one of us leads change with flexibility and decisiveness as part of our ongoing journey of personal development.”

One STADA – “Each and every one of us acts in the best interests of the company as a whole rather than our business unit or function in order to build one successful STADA.”

Quality at STADA

Quality and responsibility towards all those who use its products and services is a fundamental component of STADA’s corporate strategy. It thereby takes account of the great significance of quality in product safety in the health care market. Overall, the company aligns the quality policy throughout the Group to meet criteria that at least fulfil the strict legal requirements for pharmaceutical and health care products.

“Assessing the risks of newly arising, previously unknown side effects of active ingredients also play an important role in the quality of pharmaceutical products,” explains the astute CEO, Peter Goldschmidt. “This risk remains low for most of our products as only long-standing and researched active pharmaceutical ingredients are generally used. Of course, we have nevertheless implemented within our operations all the standard graduated plan proceedings for recording or detecting such pharmaceutical product risks throughout the Group,” he elaborated.

The Cultivated Veteran and CEO

Since September 1st, 2018, Peter Goldschmidt is the CEO of STADA Arzneimittel AG. He strongly pursues the STADA vision, to be the partner of choice in generics, speciality medicines and consumer health in Europe and selected emerging markets, while continuously outgrowing the industry in terms of growth and profitability.

Peter Goldschmidt has 30 years’ experience and success in the pharmaceutical industry. He worked in OTC, Generics and the innovative Pharma Business in Asia, Europe and the US in several different leadership functions.

Over the past three years at STADA, Peter Goldschmidt has led the group on a cultural journey, implementing a growth mindset culture based around the common purpose of “Caring for People’s Health as a Trusted Partner”. By ensuring that all of STADA’s almost 13,000 employees worldwide truly live the four STADA values of Agility, Entrepreneurship, Integrity and One STADA, he has led the group in consistently delivering above-market sales and profit growth. As a top-five supplier of both generic and consumer healthcare products in Europe, STADA helps millions of people to lead healthy, dignified and fulfilled lives.

A Glorious Vision

“Our strategic priorities and values are the basis of our entire commitment to sustainable development in order to lead sustainable business and growth while achieving a positive impact on people and their health, the economy and the environment. And we bring these to life every day. For us, caring for people’s health is more than providing support for prevention and treatment through a complete range of STADA’s quality, reliable and affordable pharmaceutical products. It also involves raising awareness of personal health care and healthy lifestyles, while supporting public health care systems. Further, it is our civic duty to act as responsible citizens – we as individuals, we as a team and a society. This is exactly what makes us a partner of trust and choice when it comes to people’s health.”

  • Peter Goldschmidt



Related Posts

Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.